| Predicted Trait | |
| Reported Trait | PR interval |
| Mapped Trait(s) | PR interval (EFO_0004462) |
| Score Construction | |
| PGS Name | PRS_PR |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | NR |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 44 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000144 |
| Citation (link to publication) | Tadros R et al. Eur Heart J (2019) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 92,340 individuals (100%) |
| PGS Evaluation | European: 100% 3 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST007045 Europe PMC: 30046033 |
92,340 individuals | European | 28 cohorts
|
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM001759 | PSS000905| European Ancestry| 1,185 individuals |
PGP000144 | Tadros R et al. Eur Heart J (2019) |
Reported Trait: Ajmaline-induced Type I Brugada syndrome electrocardiogram | OR: 1.017 [1.013, 1.022] | — | — | — | — |
| PPM001754 | PSS000904| European Ancestry| 1,257 individuals |
PGP000144 | Tadros R et al. Eur Heart J (2019) |
Reported Trait: PR slope | β: 0.22 (0.08) | — | — | — | — |
| PPM001750 | PSS000906| European Ancestry| 1,193 individuals |
PGP000144 | Tadros R et al. Eur Heart J (2019) |
Reported Trait: Baseline PR in non SCN5A mutation carriers | — | — | Correlation coefficent (r): 0.23 | — | — |
| PPM001752 | PSS000906| European Ancestry| 1,193 individuals |
PGP000144 | Tadros R et al. Eur Heart J (2019) |
Reported Trait: PR slope in non SCN5A mutation carriers | β: 0.16 (0.08) | — | Correlation coefficient (r): 0.09 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000904 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.12 | — | 1,257 individuals | — | European | — | Amsterdam | — |
| PSS000905 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.15 | — | 1,185 individuals | — | European | — | Amsterdam | — |
| PSS000906 | Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.13 | — | 1,193 individuals | — | European | — | Amsterdam | — |